Galecto (NASDAQ:GLTO) Shares Down 5.3% – Should You Sell?

Galecto, Inc. ( NASDAQ:GLTO – Get Free Report )’s stock price fell 5.3% during trading on Monday .

The stock traded as low as $5.62 and last traded at $6.02.



48,435 shares changed hands during mid-day trading, an increase of 190% from the average session volume of 16,697 shares. The stock had previously closed at $6.36.

Wall Street Analysts Forecast Growth Separately, Oppenheimer upped their price target on shares of Galecto from $9.00 to $10.00 and gave the company an “outperform” rating in a report on Thursday, October 17th.

View Our Latest Stock Analysis on GLTO Galecto Stock Performance About Galecto ( Get Free Report ) Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

Featured Stories Receive News & Ratings for Galecto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galecto and related companies with MarketBeat.com's FREE daily email newsletter ..